{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Forte Biosciences, Inc. "},"Symbol":{"label":"Symbol","value":"FBRX"},"Address":{"label":"Address","value":"3060 PEGASUS PARK DRIVE,BUILDING 6, DALLAS, Texas, 75247, United States"},"Phone":{"label":"Phone","value":"+1 310 618-6994"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Forte Biosciences Inc is a clinical-stage biopharmaceutical company, focused on dermatology. The company is developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and pediatric patients with atopic dermatitis. It plans to advance FB-401 into a randomized Phase 2 clinical trial."},"CompanyUrl":{"label":"Company Url","value":"https://www.fortebiorx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Christopher Roenfeldt","title":"Chief Operating Officer"},{"name":"Paul A. Wagner","title":"Chairman, President & Chief Executive Officer"},{"name":"Steven J. Ruhl","title":"Chief Technical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}